Table 1.
General characteristic of the sample, N = 173.
| Population characteristic | |
|---|---|
| Age, mean (SD) | 67.8 (±15.0) |
| Male sex | 116 (67.1%) |
| Pre-existing comorbidities | |
| Hypertension | 76 (43.9%) |
| Diabetes | 25 (14.5%) |
| Obesity | 10 (5.8%) |
| Vasculopathya | 24 (13.9%) |
| Clinical statusc | |
| Mild | 30 (17.3%) |
| Moderate | 74 (42.8%) |
| Severe | 69 (39.9%) |
| Clinical events | |
| Overall thrombotic events | 22 (12.7%) |
| Pulmonary embolism | 15 (8.7%) |
| Celiac trunk thrombosis | 1 (0.6%) |
| Stroke | 1 (1.1%) |
| Femoral – popliteal ischemia | 2 (1.1%) |
| Aortic thrombosis | 1 (0.6%) |
| Celiac artery | 1 (0.6%) |
| Splenic artery | 1 (0.6%) |
| Death | 44 (25.4%) |
| Cutaneous manifestations | |
| Overall | 16 (9.24%) |
| Livedo reticularisb | 9 (5.2%) |
| Acrocyanosisb | 1 (0.57%) |
| Maculo-papular rash | 6 (3.4%) |
| Concomitant therapy | |
| Antiplatelet treatment | 31 (17.9%) |
| Anticoagulant treatment | 75 (43.4%) |
| Laboratory parameters | |
| Fibrinogen [g/L] median [IQR] | 4.92 [3.60, 6.84] |
| D-dimer [microg/L] median [IQR] | 1113 [595, 2163] |
| RCP [mg/L] median [IQR] | 70.20 [3.10, 511.00] |
| WBC [109/L] median [IQR] | 8.44 [6.22, 11.60] |
| Platelet [109/L] median [IQR] | 259 [188, 340] |
| APTT [U/L] median [IQR] | 32.40 [29.50, 35.40] |
| PT [%] median [IQR] | 77 [67, 89] |
| INR median [IQR] | 1.20 [1.09, 1.32] |
| Antiphospholipid antibodies | |
| Any anti-B2GP1 or aCL | 60 (34.7%) |
| Anti-B2GP1 | 52 (30.1%) |
| IgA | 36 (20.8%) |
| IgM | 25 (14.4%) |
| IgG | 4 (2.3%) |
| ACL | 18 (10.4%) |
| IgA | 4 (2.3%) |
| IgM | 14 (8.1%) |
| IgG | 3 (1.7%) |
| Any anti-B2GP1 and aCL | 9 (5.2%) |
IQR: interquartile range; B2GP1: beta2-glycoprotein-1; aCL: anti-cardiolipin.
aDeep venous thrombosis, venous insufficiency, previous thrombo-embolic event, vasculopathic encephalopathy, and obstructive artery disease.
bOnly in two cases were these cutaneous manifestations associated to a major thrombotic event.
cClinical status = respiratory insufficiency severity and need for invasive ventilation.